A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients.

Trial Profile

A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2015

At a glance

  • Drugs Atorvastatin; BMS 582949; HMG-CoA reductase inhibitors
  • Indications Atherosclerosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 23 Mar 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 23 Mar 2011 Status changed from recruiting to completed.as reported by ClinicalTrials.gov.
    • 02 Dec 2010 Planned end date changed from 1 Jan 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top